JP2023550311A - 多発性骨髄腫の処置のための、イサツキシマブの使用 - Google Patents

多発性骨髄腫の処置のための、イサツキシマブの使用 Download PDF

Info

Publication number
JP2023550311A
JP2023550311A JP2023528113A JP2023528113A JP2023550311A JP 2023550311 A JP2023550311 A JP 2023550311A JP 2023528113 A JP2023528113 A JP 2023528113A JP 2023528113 A JP2023528113 A JP 2023528113A JP 2023550311 A JP2023550311 A JP 2023550311A
Authority
JP
Japan
Prior art keywords
individual
protein
serum
antibody
month
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550311A5 (https=
Inventor
ドロテー・シミオンド
ホアイ－トゥー・タイ
ヘルヒ・ファン・デ・フェルデ
クリスティン・ヴェイラット－フォレット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2023550311A publication Critical patent/JP2023550311A/ja
Publication of JP2023550311A5 publication Critical patent/JP2023550311A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
JP2023528113A 2020-11-03 2021-11-02 多発性骨髄腫の処置のための、イサツキシマブの使用 Pending JP2023550311A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063109305P 2020-11-03 2020-11-03
US63/109,305 2020-11-03
US202163239108P 2021-08-31 2021-08-31
US63/239,108 2021-08-31
PCT/US2021/072193 WO2022099257A1 (en) 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
JP2023550311A true JP2023550311A (ja) 2023-12-01
JP2023550311A5 JP2023550311A5 (https=) 2024-11-13

Family

ID=78825149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528113A Pending JP2023550311A (ja) 2020-11-03 2021-11-02 多発性骨髄腫の処置のための、イサツキシマブの使用

Country Status (8)

Country Link
US (1) US20220135696A1 (https=)
EP (1) EP4240416A1 (https=)
JP (1) JP2023550311A (https=)
AU (1) AU2021376374A1 (https=)
CA (1) CA3197381A1 (https=)
IL (1) IL302640A (https=)
TW (1) TW202233235A (https=)
WO (1) WO2022099257A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160020A1 (en) * 2019-01-28 2020-08-06 Sanofi Methods of treating multiple myeloma
US20200330594A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3421494A1 (en) * 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
KR20210006321A (ko) * 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
EP3969004A1 (en) * 2019-05-14 2022-03-23 Sanofi Methods of administering anti-cd38 antibody to treat multiple myeloma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160020A1 (en) * 2019-01-28 2020-08-06 Sanofi Methods of treating multiple myeloma
US20200330594A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses

Also Published As

Publication number Publication date
IL302640A (en) 2023-07-01
EP4240416A1 (en) 2023-09-13
WO2022099257A1 (en) 2022-05-12
CA3197381A1 (en) 2022-05-12
TW202233235A (zh) 2022-09-01
US20220135696A1 (en) 2022-05-05
AU2021376374A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JP7712206B2 (ja) 多発性骨髄腫の処置方法
Mould et al. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development
Mould et al. Drug development of therapeutic monoclonal antibodies
TWI860531B (zh) 用於預測細胞激素釋放症候群之多變量模型
CN109134652A (zh) Pan-ELR+ CXC 趋化因子抗体
BR112021012588A2 (pt) Proteínas de ligação anti-ctla-4 e métodos de uso destas
JP2023550311A (ja) 多発性骨髄腫の処置のための、イサツキシマブの使用
CN113747945A (zh) 用抗psma/cd3抗体治疗肾癌的方法
JP2025138745A (ja) 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
US20250177519A1 (en) Use of isatuximab in combination with other agents for the treatment of multiple myeloma
CN116761627A (zh) 艾萨妥昔单抗用于治疗多发性骨髓瘤的用途
RU2838203C2 (ru) Способы лечения множественной миеломы
RU2858309C2 (ru) Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
TWI922320B (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途
WO2025109518A1 (en) Methods for treatment of myeloproliferative neoplasms
AU2024318231A1 (en) Treatment of atopic dermatitis
TW202610683A (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260428